Pharmascience and AstraZeneca Canada among most active in pharma lobbying for 2026

‘This is an industry that is as important to the country as the aerospace industry, as the automotive industry,’ says Jim Vounassis, CEO at Pharmascience.
Health Minister Marjorie Michel met once with representatives from Pharmscience, and reps from AstraZeneca Canada twice between January and June 2026. The Hill Times photograph by Andrew Meade
News
BY TESSIE SANCI
August 24, 2026

As Health Canada looks to improve the regulatory environment for new medicines in this country, both Pharmascience and AstraZeneca Canada are two of the top organizations from the pharmaceutical sector that lobbied the most this year to discuss that work with federal officia...

To keep reading, subscribe and become a political insider.

Only $7.76 a week for an annual subscription.

Enjoy unlimited website access and the digital newspaper.

Cancel anytime.

Already a Subscriber?

Get Tuesdays: Innovation & Industry Newsletter

The policies, decisions, and people working on investment and regulation in the industry and innovation realm.

By entering your email address you consent to receive email from The Hill Times containing news, analysis, updates and offers. You may unsubscribe at any time. See our privacy policy

MOST POPULAR

MORE News

Investment summit a show of unity, but now Carney must deliver on ambition, politicos say

newsBY MARLO GLASS

Millions of driver’s licences were allegedly listed for sale on the dark web. What does it mean for Canada’s coming social media age ban?

newsBY MARIA COLLINS

Carney pitches ‘brighter future’ at Investment Summit as observers laud tax cut

newsBY PETER MAZEREEUW

‘Don’t hold your breath’: former U.S. envoy not expecting midterms to alter Trump’s tariff approach

newsBY NEIL MOSS

No ‘breakthrough’ to end nearly three-year pause in trade talks with Canada, says U.K. envoy

newsBY NEIL MOSS